Gilead Sciences has announced the launch of clinical trials for a once-a-year injectable medication aimed at preventing HIV infection. This innovative approach seeks to simplify adherence to preventive measures and could significantly enhance public health strategies in combating HIV/AIDS. The trial will enroll participants across multiple sites to evaluate the safety and efficacy of the new treatment.